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Objective: The treatment of hyperhidrosis, generalized or focal is a challenge for both
physiciansandsurgeons.Focalhyperhidrosis—axillary,palmar,plantar,craniofacial—is
the most common. Generalized hyperhidrosis is usually secondary to a systemic disor-
der or may be simply drug induced. Focal hyperhidrosis has its onset in childhood or
adolescence and has a dramatic effect on one’s quality of life. Medical, surgical, and
electrical therapies can be employed to relieve hyperhidrosis in most patients. Methods:
Areviewofthemedicalandsurgicalliteraturewasperformedtoidentifytheusualcauses
and remedies for hyperhidrosis. Results: Specific treatments, medical and surgical are
recommendedforallaffectedindividuals.Conclusion:Patientswithhyperhidrosisneed
not suffer in silence. Etiologies can be identified for most. Safe and effective therapeutic
options are available.
The primary function of the eccrine sweat glands is to assist in the maintenance of
body temperature in response to heat exposure or exercise. Hyperhidrosis may be defined
as sweating beyond what is necessary to maintain thermal equilibrium. It may be primary
(idiopathic, essential) or secondary to a number of diseases and prescribed drugs. It may
be localized, regionalized, or generalized.1 Regardless of the type or the cause of the hyper-
hidrosis,itisfrequentlysociallyembarrassingandoccupationallydisabling.Excesssweaton
thehandsmaysoilpaperandartworkandmakeitvirtuallyimpossibletoplaymanymusical
instruments. Careers in fields that require contact with paper, metal, and electrical compo-
nentsbecomeunrealizable.Axillaryandplantarhyperhidrosismayresultinstainsandcause
damagetoclothingandshoes.Generalizedorregionalizedhyperhidrosismayleaveaffected
individuals with wet clothing that may have to be changed a number of times each day.
Physiologically, sweating is a function of the sympathetic nervous system. A sweat
control center located in the preoptic area and anterior hypothalamus contains neurons that
are sensitive to changes in internal temperature and also to cerebral cortical events. Sweat
glandsareinnervatedbysympatheticpostganglionicfibers,butunlikeordinarysympathetic
innervationsthechemicalmediatorisacetylcholine.Sweatinginresponsetothermalstimuli
isgenerallyacceptableandrarelyacauseforcomplaint.Emotionallyinducedsweatingtends
to be localized to the palms, soles, and sometimes the forehead. Axillary sweating may be
the result of both emotional and thermal stimuli.
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Table 1. Hyperhidrosis
Generalized
Heat, humidity, and exercise
Febrile illnesses: acute and chronic infections
Neoplasia: Hodgkin’s disease
Metabolic: carcinoid, diabetes mellitus, gout, hyperpituitarism, hypoglycemia, menopause,
pheochromocytoma, and thyrotoxicosis
Sympathetic discharge: shock and syncope, intense pain, alcohol and drug withdrawal
Neurologic: Riley-Day syndrome, Ross syndrome, and irritative hypothalamic lesions
Drugs: propanolol, physostigmine, pilocarpine, tricyclic antidepressants, and venlafaxine
Table 2. Hyperhidrosis
Localized
Heat
Olfactory
Gustatory: citric acid, coffee, chocolate, peanut butter, and spicy foods
Neurologic lesions/Frey syndrome
Primary or focal hyperhidrosis
The causes for generalized hyperhidrosis (Table 1) include a number of febrile ill-
nesses, neoplastic and neurologic diseases, metabolic disorders, and drugs. The causes
and conditions associated with localized hyperhidrosis (Table 2) include primary or fo-
cal hyperhidrosis, unilateral circumscribed hyperhidrosis, hyperhidrosis associated with
intrathoracic neoplasms, olfactory hyperhidrosis, gustatory hyperhidrosis, spinal cord in-
juries, and Frey syndrome. Although primary or focal hyperhidrosis is the most common
cause of palmoplantar hyperhidrosis, it may also occur in some patients with Raynaud’s
disease, rheumatoid arthritis, erythromelalgia, nail patella syndrome, keratosis palmaris et
plantaris with clinodactyly, atrioventricular fistula, and cold injury. Whenever possible, the
cause for hyperhidrosis should be identified and, if possible, treated.
Primary or focal hyperhidrosis is a disorder in which there is excess sweating of the
hands, feet, face, and the axillae. A recent national survey estimated that 1.4% of the US
population (4.0 million individuals) suffers from axillary hyperhidrosis.2 One third of these
sufferers (1.3 million individuals) state that their sweating is barely tolerable or intolera-
ble and frequently or always interferes with their daily life. Primary hyperhidrosis may be
inherited and in contrast to generalized hyperhidrosis usually has its time of onset in child-
hood or adolescence.3 Palmar hyperhidrosis usually commences in childhood and axillary
hyperhidrosis in adolescence. Characteristically, focal hyperhidrosis does not occur while
sleeping. Primary hyperhidrosis is aggravated by heat and emotional stimuli. However, it is
important to note that although emotional stimuli are necessary for primary hyperhidrosis
to occur in affected individuals, it is not a psychological disease but rather a physiological
disorder. It seems that in patients with primary hyperhidrosis the hypothalamic sweat cen-
ters are more sensitive to emotional stimuli of cerebral origin than in ordinary people. The
occasional onset of primary hyperhidrosis in the neonatal period is evidence that this is far
more than an emotional disorder!
A number of medical and surgical remedies are available for the treatment of hyper-
hidrosis. (Table 3)
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Table 3. Treatment of hyperhidrosis
∗
Medical
Topical
Antiperspirants: Aluminum hexahydrate in alcohol (Drysol)
2%–5% Tannic acid solution
5%–20% Formalin solution
10% Glutaraldehyde solution
Anticholinergics: 0.5% glycopyrrolate lotion
Systemic
Tranquilizers: diazepam (Valium), fluoxetine (Prozac)
Anticholinergics: propantheline bromide (Banthine/Probanthine), methoscopolamine bromide (Pamine),
glycopyrrolate (Robinul), oxybutynin (Ditropan), & benztropine mesylate (Cogentin)
NSAIDs: indomethacin
Calcium channel blockers: diltiazem (Cardizem), Clonidine hydrochloride (Catapres), &
botulinum toxin type A (Botox)
Surgical
Sympathectomy
Axillary sweat gland removal surgical procedures
Electrical
Iontophoresis
∗NSAIDs indicates nonsteroidal anti-inflammatory drugs.
TOPICAL
Aluminum chloride and tanning agents are sometimes effective in the control of localized
hyperhidrosis.4 Aluminum chloride may decrease sweating by mechanically obstructing
eccrine sweat gland pores, although this mechanism has been disputed. The atrophy of the
secretory cells seen in eccrine sweat glands exposed to aluminum chloride may account
for the reduced sweating that most people enjoy with the use of aluminum chloride con-
taining products. For most people with axillary hyperhidrosis, over-the-counter products
are sufficient. For more severe sweating, aluminum chloride hexahydrate (20%) dissolved
in anhydrous ethyl alcohol (Drysol) is frequently useful. The skin should be dry before
application, because if moisture is present irritating hydrochloric acid forms. Washing just
before application should be avoided. The optimum way to use the solution seems to be to
apply it at bedtime to take advantage of the relative inactivity of sweat glands through the
night and wash the product off first thing in the morning. Minor irritation can be relieved
with the use of hydrocortisone creams. The solution should be used nightly until an effect
occursandthentheintervalbetweenapplicationscanbelengthened.Glutaraldehyde,tannic
acid, and formaldehyde may be useful to treat palmar and plantar hyperhidrosis, but their
tendency to stain the skin and in the case of formaldehyde solution its sensitizing potential
limit their usefulness.5
SYSTEMIC
For those patients whose hyperhidrosis is related to specific anxiety-producing events such
as a speaking engagement, school dance, the use of a drug such as diazepam (Valium)
may have an ameliorating effect. If hyperhidrosis is a part of a social anxiety disorder,
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fluoxetine (Prozac) may be a very useful therapeutic agent along with appropriate psychi-
atriccare.Systemicanticholinergicsmaybehelpful,butunfortunatelythedosagesrequired
to achieve reduced sweating also result in adverse effects including xerostomia, mydriasis,
cycloplegia, and bowel and bladder dysfunction. Most patients with localized or general-
ized hyperhidrosis cannot tolerate them for long. However, the anticholinergic oxybutynin
(Ditropan) has been found to be useful in the relatively rare syndrome of episodic hyper-
hidrosis with hypothermia.6 Another anticholinergic, benztropine, was successfully used to
treat hyperhidrosis in a patient with venlafaxine-induced excess sweating.7 Venlafaxine is
an antidepressant that inhibits the reuptake of serotonin and norepinephrine. Sweating is
said to occur in as many as 12% of all patients exposed to venlafaxine and other serotonin
selective reuptake inhibitors. A nonsteroidal anti-inflammatory agent, indomethacin, in a
dose of 25 mg tid was prescribed for a patient with arthritis who coincidentally had lifelong
idiopathic generalized hyperhidrosis.8 Quite unexpectedly, she enjoyed a resolution of her
lifelong hyperhidrosis. Although the mechanism for this beneficial effect is not clear, the
informationthatprostaglandinEisfoundinincreasedamountsinthesweatofsomepatients
with hyperhidrosis may offer an explanation.9 Influx of calcium from the extracellular to
the intracellular space is necessary for the active secretion of sweat by eccrine sweat glands.
This likely accounted for the improvement in palmar and plantar hyperhidrosis observed
when a calcium channel blocker, diltiazem, was used to treat a family with palmar and
plantar hyperhidrosis.10 Tricyclic antidepressants may cause excess sweating and yet, one
would expect the anticholinergic action of tricyclics should block sweating not induce it.
Clonidine(Catapres),acentrallyactiveα-adrenergicautoreceptorstimulant,hasbeenfound
to be useful in the treatment of hyperhidrosis because of tricyclics as well as menopause.11
Propoxyphene hydrochloride (Darvon), a narcotic and weak ganglionic blocking agent,
may have an ameliorating effect on hyperhidrosis in patients with autonomic dysreflexia.12
Autonomic dysreﬂexia is a syndrome of sympathetic hyperactivity because of bladder or
bowel distension, seen in some patients with spinal cord lesions at or above the 6th thoracic
level (T6). Fludrocortisone acetate (0.3 mg daily) may control sweating in quadriplegics
for whom orthostatic hypotension precipitates a sympathetic discharge.13 The reader is
cautioned that many of these reports of therapeutic efficacy are anecdotal and all of these
systemic agents carry with them the risk of side effects.
IONTOPHORESIS
One of the simplest, safest, and most cost-effective treatments of palmar and/or plantar
hyperhidrosis is that of iontophoresis, which is defined as the introduction of an ionized
substance through intact skin by the application of a direct current. In 1936, Ichihashi used
various solutions of atropine, histamine, and formaldehyde, and by iontophoresis demon-
strated that sweating of the palms could be reduced.14 His work went relatively unnoticed
until 1952 when Bouman and Gruenwald Lentzer published a report clearly demonstrating
the efficacy of iontophoresis for the treatment of palmar and plantar hyperhidrosis in 113
patients.15 They demonstrated that the addition of an ionizable substance to the water was
not necessary to obtain a therapeutic effect. Levit demonstrated a simple galvanic device
that could be employed to relieve hyperhidrosis in 85% of affected patients.16,17
Althoughtheexactmechanismofapplyingiontophoresisthatrelievespalmarorplantar
hyperhidrosis is not known, it is thought to be due to poral plugging because the effect is
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Table 4. Iontophoresis for hyperhidrosis with the Fischer Galvanic Unit
∗
A: Iontophoresis of hands using an assistant to control the unit
1. Fill the 2 plastic trays with tap water at room temperature to the top of the electrodes.
2. With the Fischer unit off, connect the trays to the unit’s outputs with the supplied cords.
3. Make certain, the patient removes all jewelry and any small cuts or abrasions are covered with Vaseline or
some similar water-resistant material.
4. With the unit still off, have patient place 1 hand in each tray. The water level should be just above the skin
of the tops of the fingers and hands. Remind the patient to keep hands in the water for complete duration.
Removing the hands or touching the electrodes during the treatment may result in a slight shock. Because
the intensity of the current flow is greatest at that part of the hand that is closest to the electrodes, instruct
the patient to rotate their hands using a sliding motion away from the electrodes to avoid any unusual
discomfort.
5. Turn unit on with meter scale set from 0 to 50 and “intensity” knob at zero and gradually increase the
amperage using the intensity knob to the therapeutic range of 15 to 18 mA, and treat for 10 min. (Note: If
the red “active” light does not illuminate when you begin to increase current flow, return to zero and check
all connections.)
6. At the end of the 10 min, decrease current flow gradually to zero.
7. When the meter indicates the flow is zero and the active light goes out, change the direction of current flow
at the unit with the “Nor-Rev” toggle switch.
8. Repeat steps (5) and (6) for 10 min. The total treatment duration will be 20 min.
∗If the feet and not the hands are being treated, the patient once taught may adjust the controls him/herself.
Table 5. Iontophoresis for hyperhidrosis with the Fischer Galvanic Unit
B: Iontophoresis of the hands and feet without an assistant
Note: This technique allows 1 hand to be free so that the patient can control the unit. However, the total
duration of the treatment is increased from 20 to 40 min (20 min for each hand and foot combination).
1. Place 1 tray on a table and the other on the floor.
2. Place 1 hand in 1 tray and a foot in the second.
3. Follow instructions (5) to (8) above.
4. Remove hand and foot and insert untreated hand and foot and repeat (5) to (8) above.
Notes
1. If the mineral content of the tap water is low and current flow is reduced, then the desired amperage (15 to
18 mA) may not be achieved. A teaspoonful of baking soda added and dissolved in each tray should
remedy the problem.
2. Patients need treatments every 2 to 3 days for 5 to 10 sessions before an effect is observed. Once euhidrosis
is achieved, the interval between treatments may be stretched out. Some patients need only treat themselves
once every 2 to 4 weeks.
3. Avoid treating patients who are pregnant or have pacemakers.
4. Patients who fail to respond to simple tap water iontophoresis may benefit from the addition of an
anticholinergic to the water, ie, Robinul Forte 2 mg crushed and dissolved in each tray.
5. Some patients experience irritation along the water line following treatment. One percent hydrocortisone
cream is usually sufficient to relieve this.
reversed by cellophane tape stripping of the skin overlying eccrine sweat gland rendered
euhidrotic by iontophoresis.18,19 For those patients who fail to respond to simple tap-water
iontophoresis the addition of an anticholinergic directly to the tap water-filled treatment
trays is frequently helpful.
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Althoughanumberofdevicesareavailablefortheadministrationofiontophoresis,this
author prefers the Fischer MD-1a Galvanic unit and the technique employed is described in
Tables4and5.Sideeffectsofiontophoresisarefew.Occasionallythepalmsbecometoodry
andmaybecomecrackedorfissured.Thismayberelievedbytheuseofmoisturizersand/or
a reduction in the frequency of treatments. Erythema and less frequently vesiculation of the
skin may follow treatments and can be treated if necessary with simple 1% hydrocortisone
cream. Compensatory hyperhidrosis does not occur. Iontophoresis is difficult to administer
to the axillae and seems to cause more irritation than when administered to the palms and
soles and thus is not as useful for the treatment of axillary hyperhidrosis.
BOTULINUM TOXIN
Justinus Kerner, a German physician and poet, published the first comprehensive descrip-
tion of the symptoms of botulism between 1817 and 1822. He also proposed the possible
therapeutic use of botulinum toxin, which he called sausage poison. Kerner’s monograph
describesthefollowingillnessfromingestinginadequatelycookedsmokedblood-sausages.
The tear fluid disappears, the gullet becomes a dead and motionless tube; in all mucous cavities of the
human machine the secretion of the normal mucus stands still, from the biggest, the stomach, towards
the tear canal and the excretory ducts of the lingual glands. No saliva is secreted. No drop of wetness
is felt in the mouth, no tear is secreted any more—Urination can only be performed by standing and
with difficulty. Extreme drying out of the palms, the soles, and the eyelids occurs.
Kerner went on to describe in humans and animals vomiting, intestinal spasms, mydriasis,
ptosis, dysphagia, and in the end, respiratory failure. His reputation as an expert on sausage
poisoning earned him the nickname Sausage Kerner. Subsequently sausage poisoning was
named botulism from the Latin word for sausage, botulus. Years later in 1895 the bacterium
responsible for botulism was identified by Emil-Pierre van Ermengem.20
Today, botulinum toxin is a useful therapeutic agent for the treatment of a number of
diseases related to muscular dystonia. This potent toxin has proven to be a highly effective
remedyforthetreatmentofconditionspreviouslyrecalcitrantinthefieldsofophthalmology,
otorhinolaryngology, pediatrics, gastroenterology, and urology. The cosmetic denervation
of muscles of facial expression using botulinum toxin has given dermatologists and plastic
surgeons a new weapon against facial expression-induced wrinkles and lines. In recent
years, certain types of hyperhidrosis have been successfully treated with botulinum toxin.
Side effects reported following the local injection of botulinum toxin have been few and
are usually related to undesired weakness in muscles adjacent to the treatment sites.
TREATMENT OF AXILLARY HYPERHIDROSIS
Patientswithquality-of-lifeimpairingaxillaryhyperhidrosis,unresponsivetotopicalreme-
dies, should be offered treatment with either botulinum toxin or surgical ablation of the
axillary sweat glands. Because botulinum toxin inhibits the release of acetylcholine not
only at neuromuscular junctions but also in postganglionic sympathetic fibers to sweat
glands, it has been found to be useful to treat axillary hyperhidrosis.21–26 In the treatment
of axillary hyperhidrosis as little as 50 units injected and distributed intradermally to each
axilla can produce euhidrosis lasting as long as 6 months. With larger doses responses
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have been as long as 15 months. Many clinicians perform a starch-iodine test prior to the
treatment to document the extent of the hyperhidrosis and to identify any so-called “hot
spots,” which are areas that produce greater amounts of sweat. This author uses a simple
facial tissue and a gentian violet marker to identify such areas. Generally, the hyperhidrosis
occurs in the hair bearing part of the axillae and so it is in this area that the toxin should be
placed. Discomfort is minimal and simple ice packs applied to the axillae prior to injection
are sufficient for anesthesia. Botulinum toxin type A in an appropriate vehicle and applied
directly to the axillae may prove to be an effective treatment.27
Patients with axillary hyperhidrosis who are unresponsive to topical therapy or do not
want botulinum toxin or in whom it is contraindicated or who simply want a more long-
lastingremedymaybeofferedavarietyofsurgicaltechniquesdesignedtoablatetheaxillary
sweatglands.Theareasofgreatestsweatproductionmaybeidentifiedbydrapingapieceof
facial tissue paper over the axilla or a starch-iodine test. Sometimes this area is quite small
andasimpleexcisionwithclosureissufficienttoremedytheproblem.28 Patientsinthepast
with moderate to severe hyperhidrosis have been offered more extensive procedures with
undermining and resection of all exposed sweat glands.29 To obtain good closure and avoid
limitationofmovementbecauseofcicatricialcontracture,Z-plasty,andbat-shapedexcisions
and repairs can be employed.30 A promising arthroscopic shaver technique has recently
been described, which is efficacious and is associated with a high-satisfaction rate and
low morbidity.31 Alternative equally effective surgical treatments for axillary hyperhidrosis
include subcutaneous liposuction with or without subcutaneous curettage.32,33
TREATMENT OF PALMAR/PLANTAR HYPERHIDROSIS
Patientswithpalmarorplantarhyperhidrosisshouldbegivenatrialofaprescriptionstrength
antiperspirant such as aluminum chloride hexahydrate (20%) dissolved in anhydrous ethyl
alcohol prior to botulinum toxin or iontophoresis treatments.34 Botulinum injections are
very effective for the treatment of palmar hyperhidrosis.35–37 Generally the doses used are
higherthanthoseusedforaxillaryhyperhidrosisrangingfrom100to200unitsofbotulinum
toxin type A per hand. Euhidrosis following such treatment may last for as long as a
year.
Although effective, the clinical usefulness of this treatment is limited by the need
for repetitive relatively painful injections, the cost of the botulinum toxin, and reports of
weakness of the small muscles of the hands.35
Anesthesia is mandatory for the administration of botulinum toxin to the hand or feet.
Although topical anesthesia in the form of lidocaine topical under occlusion for an hour
followed by ice packs seems satisfactory for some, most practitioners have found the need
for a either a Bier block or a block of the median, ulnar, and radial nerves.38 The Bier block,
once learned, not only is safe and effective but also carries with it the advantage over nerve
blocks of not affecting motor function. Thus patients can still use their hands immediately
after the treatment. A simple and remarkably effective form of anesthesia is that of ice cube
anesthesia during which an ice cube, held in gauze, is applied just prior to each individual
injection of botulinum toxin type A.
Iontophoresis still remains a useful therapy because botulinum toxin injections for the
treatmentofpalmarandplantarhyperhidrosisarenotsuitableforallpatients.34 Specifically,
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musicians,surgeons,andotherswhodependonfinemotordexterityintheirhandsmaynotbe
abletoaccepttherisksofdiminishedstrengthoftheirthumbsthatmayaccompanybotulinum
toxin injections. Young children may not accept the discomfort involved in either regional
nerve blocks or a Bier block for the anesthesia or even ice cube anesthesia for botulinum
injections into the hands. Finally, iontophoresis is far less costly than botulinum treatments
ofpalmarandplantarhyperhidrosiskeepinginmindthatfrom100to200unitsofbotulinum
toxin are used per hand and an anesthetic/administration fee may be involved.
TREATMENT OF CRANIOFACIAL HYPERHIDROSIS
Craniofacialhyperhidrosismayrespondtotopicalantiperspirantssuchasaluminumchloride
hexahydrate (20%) dissolved in anhydrous ethyl alcohol or topical glycopyrrolate. Topical
glycopyrrolate has been found to be useful to treat gustatory craniofacial hyperhidrosis in
patients with diabetes.39 Botulinum toxin is very effective for craniofacial hyperhidrosis
and is considered the treatment of choice for patients with Frey syndrome. Frey syndrome
is characterized by unilateral gustatory hyperhidrosis that occurs in as many as 50% of
patients who have undergone a parotidectomy.40 The most likely explanation is recurrence
of parasympathetic nerve fibers that have lost their target organ. When botulinum toxin
is used to treat craniofacial hyperhidrosis, the technique differs from that used to treat the
facial musculature in that the injections are more superficial, that is, intradermal and evenly
distributedovertheareaofhyperhidrosis.Theareamaybeidentifiedbyeitherstarch-iodine
technique or a facial tissue held against the skin. Botulinum toxin, 50 to 100 units, should
be administered at least 11 /2 cm above the supraorbital bridge to avoid a brow drop.
SYMPATHECTOMY
Sympathectomyorupperthoracic(T2)ganglionectomyisfrequentlyofferedtopatientswith
severe palmar hyperhidrosis and occasionally craniofacial hyperhidrosis. Lumbar sympa-
thectomy is not usually employed for plantar hyperhidrosis because of the risk of sexual
dysfunction. Although the efficacy of this procedure used in the treatment of palmar hy-
perhidrosis is not in doubt, with success rates of 92% to 99%, the complications are sig-
nificant. Among the complications are compensatory hyperhidrosis (increased sweating
in some other area of the body, 24% to 100%), gustatory sweating (sweating usually of
the face related to the eating of foods), permanent Horner syndrome, wound infection,
hemothorax, intercostal neuralgia, and recurrence of hyperhidrosis.41–50 The advent of en-
doscopic sympathectomy has reduced the incidence of many complications. Compensatory
hyperhidrosis is the most common complication and the major reason for patient dissatis-
faction with the procedure. Compensatory hyperhidrosis following sympathectomy can be
far more life disrupting than palmar hyperhidrosis in that afflicted individuals may have to
change sweat-soaked clothing 2 or 3 times a day. In a recent systematic literature review of
sympathectomy for the treatment of hyperhidrosis, the question was asked, “Are we paying
a high price for surgical sympathectomy?” One hundred thirty-five articles were reviewed
reporting on 22,458 patients and 42,061 procedures, and 84.3% of the reported patients had
the surgery for hyperhidrosis. Compensatory hyperhidrosis occurred in 52.3%, gustatory
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sweating in 32.3%, phantom sweating in 38.6%, and Horner syndrome 2.4%. In all, neu-
ropathic complications occurred in 11.9% but were less common in patients who had the
procedure for hyperhidrosis.50
Moran stated it quite succinctly,
“Complications related to the surgical approach, such as Horner’s syndrome, brachial
plexusinjuries,pneumothoraxandpainfulscarsmayoccur,whilefollowingsympathectomy
compensatory hyperhidrosis is usual and hyperhidrosis may recur.”47
SUMMARY
The patient who complains of hyperhidrosis presents the physician with a diagnostic and
therapeutic challenge. Patients who present with generalized hyperhidrosis are in general
adults whose sweating occurs during both the waking and sleeping hours. Such patients
require a search for a remedy that may sometimes be as simple as a drug that they are
takingforsomemedicaldisorder.Occasionallyasystemicillnessmayaccountfortheonset
of hyperhidrosis and a thorough examination and appropriate testing may be necessary to
identify the cause. Most patients with primary or focal hyperhidrosis present in childhood
oradolescenceandhaveaproblemlocalizedtotheiraxillae,hands,and/orfeet.Theyhavea
neurocutaneousdisordernotapsychiatricorendocrinologicdisease.Anumberofsystemic,
topical, surgical, and electrical remedies are available for the treatment of hyperhidrosis.
Patients with axillary hyperhidrosis may benefit from prescription-strength antiperspirants.
For those who do not improve, botulinum toxin type A is frequently helpful. Surgical
methods, refined in recent years, such as liposuction with or without curettage are effective
alternative remedies. Patients with hyperhidrosis of the palm or soles, who fail to respond
to topical agents, deserve a trial of conservative therapy, botulinum toxin, or iontophoresis,
before aggressive surgical techniques that carry with them the risk of lifelong troublesome
side effects are offered.
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